Republic of the Philippines

CAVITE STATE UNIVERSITY

(CvSU)
Don Severino Delas Alas Campus
Indang, Cavite
(046) 4150-010 / 4150-011 (046) 4150-012

DRUG STUDY
NAME OF PATIENT: JB DATE OF ADMISSION: AUGUST 6, 2014
AGE: 42 YEARS OLD DIAGNOSIS: POST CHOLELITHIASIS
SEX: MALE
Drug Features
Mechanism of
Action
Indication

Contraindication

Effects Nursing Responsibilities
Generic Name:
CEFRADINE
Brand Name:
none
Classification:
ANTIBACTERIAL
Sub Classification:
NONE
Dosage:
1 g
Route:
IV
Frequency:
Q 8
Form:
Powder in ampule
Color:
WHITE
Binds to bacterial
cell wall
membrane,
causing cell death.
Therapeutic
Effects: Inhibit
growth of
(bacteriostatic)
susceptible
pathogenic
bacteria. Not
active against
viruses or fungi.
Treatment of the
following infections
caused by
susceptible
organisms: : Lower
respiratory tract
infections, Skin and
skin structure
infections, Bone and
joint infections,
Urinary tract
infections,
Gynecological
infections, Intra-
abdominal infections,
Septicemia.
Perioperative
prophylaxis.
Known
hypersensitivity to
individual agents.
Cross sensitivity
among related
agents may occur.







Side Effects
Swelling, redness, pain, or
soreness at the injection
site, loss of appetite,
nausea, vomiting,
diarrhea, or headache
Adverse Effects
CNS: SEIZURES (HIGH
DOSES). GI:
PSEUDOMEMBRANOUS
COLITIS, diarrhea, nausea,
vomiting. Derm: rashes,
urticaria. Hemat: bleeding,
eosinophilia, hemolytic
anemia, leukopenia,
thrombocytopenia. Local:
pain at IM site, phlebitis at
IV site. Misc: ALLERGIC
REACTIONS INCLUDING
ANAPHYLAXIS,
superinfection.
Check for Doctors order
Observe 10Rs of the patient in medicine
administration
Assess for infection (vital signs; appearance of
wound, sputum, urine, and stool; WBC)
at beginning of and throughout therapy.
Before initiating therapy, obtain a history to
determine previous use of and reactions
to penicillins or cephalosporins. Persons
with a negative history of penicillin
sensitivity may still have an allergic
response.
Obtain specimens for culture and sensitivity
before initiating therapy. First dose may
be given before receiving results.
Observe patient for signs and symptoms of
anaphylaxis (rash, pruritus, laryngeal
edema, wheezing). Discontinue the drug
and notify health care professional
immediately if these symptoms occur.
Keep epinephrine, an antihistamine, and
resuscitation equipment close by in the
event of an anaphylactic reaction.
Monitor bowel function. Diarrhea, abdominal
cramping, fever, and bloody stools
should be reported to health care
professional promptly as a sign of
pseudomembranous colitis. May begin
up to several weeks following cessation
of therapy.
Lab Test Considerations: May cause positive


results for Coombs' test, especially in
patients with azotemia.
May cause serum AST, ALT, alkaline
phosphatase, bilirubin, LDH, BUN, and
creatinine.
May cause falsely elevated test results for
serum and urine creatinine; do not
obtain serum samples within 2 hr of
administration.
May rarely cause leukopenia, neutropenia,
agranulocytosis, thrombocytopenia, and
eosinophilia. Patient & Family Education
Advise patient to report signs of
superinfection (furry overgrowth on the
tongue, vaginal itching or discharge,
loose or foul-smelling stools) and allergy.
Instruct patient to notify health care
professional if fever and diarrhea develop,
especially if stool contains blood, pus, or
mucus. Advise patient not to treat diarrhea
without consulting health care professional.
SUBMITTED BY: ANGELICA CASSANDRA P. VILLENA CLINICAL INSTRUCTOR: NORMIDIA QUION, RN, MAN
YEAR & SEC. GRP: BSN 3 1 GRP 1
DATE: AUGUST 9, 2014